It is worth noting that the use of selective β3-AR agonists comes with challenges as some of the β3-AR agonists have been approved to treat overactive bladder and urinary incontinence (20–22), but none of them have been approved to treat metabolic diseases. The gene discussed is ADRB3; the disease is metabolic disease.